<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药融投资 | wechat-feeds</title><link>http://Mzg5OTA1NDgzMg.favicon.privacyhide.com/favicon.ico</link><description>医药行业</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 01 Jun 2021 12:40:05 +0800</pubDate><image><url>http://Mzg5OTA1NDgzMg.favicon.privacyhide.com/favicon.ico</url><title>药融投资 | wechat-feeds</title><link>http://Mzg5OTA1NDgzMg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>北京五和博澳药业，科创板上市辅导中</title><link>https://mp.weixin.qq.com/s/cbPXKv6RTYVetM555fAA2g</link><description></description><content:encoded><![CDATA[北京五和博澳药业，科创板上市辅导中]]></content:encoded><pubDate>Tue, 01 Jun 2021 09:04:50 +0800</pubDate></item><item><title>纽福斯和霍德生物达成战略合作 | 共同开发基于iPSC的眼科疾病细胞疗法</title><link>https://mp.weixin.qq.com/s/l4G-Hx-p5zY9KOcFDc96yg</link><description></description><content:encoded><![CDATA[纽福斯和霍德生物达成战略合作 | 共同开发基于iPSC的眼科疾病细胞疗法]]></content:encoded><pubDate>Tue, 01 Jun 2021 09:04:50 +0800</pubDate></item><item><title>低调药企，坐标北京：拟从申报科创板转主板上市</title><link>https://mp.weixin.qq.com/s/_cc510Gpjta6IJUM3SmgFA</link><description></description><content:encoded><![CDATA[低调药企，坐标北京：拟从申报科创板转主板上市]]></content:encoded><pubDate>Thu, 27 May 2021 11:02:33 +0800</pubDate></item><item><title>全球疫苗竞赛烽烟四起，新锐丽珠新冠疫苗临床进展显著</title><link>https://mp.weixin.qq.com/s/7MGbociVlCtmJNvWwo1wNw</link><description></description><content:encoded><![CDATA[全球疫苗竞赛烽烟四起，新锐丽珠新冠疫苗临床进展显著]]></content:encoded><pubDate>Thu, 27 May 2021 11:02:33 +0800</pubDate></item><item><title>火热股：和元生物辅导结束，2020年业绩同比翻倍</title><link>https://mp.weixin.qq.com/s/THzjZQgN87eFK9OQ63v-3A</link><description></description><content:encoded><![CDATA[火热股：和元生物辅导结束，2020年业绩同比翻倍]]></content:encoded><pubDate>Wed, 26 May 2021 15:29:04 +0800</pubDate></item><item><title>2021中国（苏州）抗体药物、细胞和基因治疗峰会”ACGT China (Suzhou) 2021</title><link>https://mp.weixin.qq.com/s/TFejtp3HLYEMYTNoAtc9Lw</link><description></description><content:encoded><![CDATA[2021中国（苏州）抗体药物、细胞和基因治疗峰会”ACGT China (Suzhou) 2021]]></content:encoded><pubDate>Wed, 26 May 2021 15:29:04 +0800</pubDate></item><item><title>重磅！国知局：10亿级仑伐替尼制剂专利无效，继晶型后</title><link>https://mp.weixin.qq.com/s/IVoZ6CZbcG5ebJoyoEhBAw</link><description></description><content:encoded><![CDATA[重磅！国知局：10亿级仑伐替尼制剂专利无效，继晶型后]]></content:encoded><pubDate>Wed, 26 May 2021 15:11:13 +0800</pubDate></item><item><title>六月重庆：十余位原FDA/CDE专家共话创新制剂及改良型新药峰会</title><link>https://mp.weixin.qq.com/s/TkFSJNspiVcHauAzzDkqTg</link><description></description><content:encoded><![CDATA[六月重庆：十余位原FDA/CDE专家共话创新制剂及改良型新药峰会]]></content:encoded><pubDate>Wed, 26 May 2021 15:11:13 +0800</pubDate></item><item><title>【8月重磅】中国AI新药合作大会来袭</title><link>https://mp.weixin.qq.com/s/lCJD3RqesHgpmElTbSHNow</link><description></description><content:encoded><![CDATA[【8月重磅】中国AI新药合作大会来袭]]></content:encoded><pubDate>Wed, 26 May 2021 15:11:13 +0800</pubDate></item><item><title>【2021 ASCO】ORR逾80%！亚盛Bcl-2抑制剂APG-2575治疗复发难治CLL/SLL显疗效！</title><link>https://mp.weixin.qq.com/s/024x3Y1tEOMqabLUvRZvDw</link><description></description><content:encoded><![CDATA[【2021 ASCO】ORR逾80%！亚盛Bcl-2抑制剂APG-2575治疗复发难治CLL/SLL显疗效！]]></content:encoded><pubDate>Thu, 20 May 2021 08:42:39 +0800</pubDate></item><item><title>十余位原FDA/CDE/千人共话创新制剂及改良型新药峰会</title><link>https://mp.weixin.qq.com/s/yyWZTwF7YqLOicahf_KOPg</link><description></description><content:encoded><![CDATA[十余位原FDA/CDE/千人共话创新制剂及改良型新药峰会]]></content:encoded><pubDate>Thu, 20 May 2021 08:42:39 +0800</pubDate></item><item><title>【重磅】中国AI新药合作大会来袭</title><link>https://mp.weixin.qq.com/s/aI8Fq1jyLTtDTRH0d2rgRg</link><description></description><content:encoded><![CDATA[【重磅】中国AI新药合作大会来袭]]></content:encoded><pubDate>Thu, 20 May 2021 08:42:39 +0800</pubDate></item><item><title>勃林格殷格翰，全球最富有家族之一创立的药企</title><link>https://mp.weixin.qq.com/s/wNTOWwJ4PLs5wJfTsS_d8A</link><description></description><content:encoded><![CDATA[勃林格殷格翰，全球最富有家族之一创立的药企]]></content:encoded><pubDate>Wed, 19 May 2021 09:33:37 +0800</pubDate></item><item><title>十余位原FDA/CDE/千人共话创新制剂及改良型新药峰会</title><link>https://mp.weixin.qq.com/s/D9WQMKHYWKUWkCt_wpzxiQ</link><description></description><content:encoded><![CDATA[十余位原FDA/CDE/千人共话创新制剂及改良型新药峰会]]></content:encoded><pubDate>Wed, 19 May 2021 09:33:37 +0800</pubDate></item><item><title>【重磅】中国AI新药合作大会来袭</title><link>https://mp.weixin.qq.com/s/ZmdjQ2eLghslHhJZ36sNPw</link><description></description><content:encoded><![CDATA[【重磅】中国AI新药合作大会来袭]]></content:encoded><pubDate>Wed, 19 May 2021 09:33:37 +0800</pubDate></item><item><title>亚盛医药（6855.HK）获纳入MSCI中国小型指数成份股</title><link>https://mp.weixin.qq.com/s/TkDjwPoxFcjVx6VVlI_UrA</link><description></description><content:encoded><![CDATA[亚盛医药（6855.HK）获纳入MSCI中国小型指数成份股]]></content:encoded><pubDate>Thu, 13 May 2021 10:21:21 +0800</pubDate></item><item><title>大咖云集共话热点 ，这个高端制剂/改良新药峰会不一般！</title><link>https://mp.weixin.qq.com/s/qtrAY3aeMUWMAcVLNMTWJw</link><description></description><content:encoded><![CDATA[大咖云集共话热点 ，这个高端制剂/改良新药峰会不一般！]]></content:encoded><pubDate>Thu, 13 May 2021 10:21:21 +0800</pubDate></item><item><title>重磅！健信生物完成A轮融资，加速PD-1后时代双抗产品开发</title><link>https://mp.weixin.qq.com/s/o7y4q1uOmp4W7Ml2iAzHMg</link><description></description><content:encoded><![CDATA[重磅！健信生物完成A轮融资，加速PD-1后时代双抗产品开发]]></content:encoded><pubDate>Thu, 13 May 2021 10:21:21 +0800</pubDate></item><item><title>就在后天！大湾区(广州)生物医药创新者峰会：千名医药人将共聚一堂</title><link>https://mp.weixin.qq.com/s/blhipDg5KdcMdE2o8Earcw</link><description></description><content:encoded><![CDATA[就在后天！大湾区(广州)生物医药创新者峰会：千名医药人将共聚一堂]]></content:encoded><pubDate>Sun, 09 May 2021 16:51:50 +0800</pubDate></item><item><title>大咖云集共话热点 ，这个高端制剂/改良新药峰会不一般！</title><link>https://mp.weixin.qq.com/s/a0qhBy_oJH3B62GytLv8nQ</link><description></description><content:encoded><![CDATA[大咖云集共话热点 ，这个高端制剂/改良新药峰会不一般！]]></content:encoded><pubDate>Sun, 09 May 2021 16:51:50 +0800</pubDate></item></channel></rss>